Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor

Scandinavian Journal of Rheumatology

Volumn 37, Issue 5, 2008, Pages 321-328

  Engvall, I L ^a   Elkan, A C ^a   Tengstrand, B ^a   Cederholm, T ^b   Brismar, K ^c   Hafstrom I ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; SOMATOMEDIN;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CACHEXIA; DISEASE ACTIVITY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE MASS; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CACHEXIA; CASE-CONTROL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; THINNESS;

EID: 52949136215     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802055984     Document Type: Article

References (62)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002;85:89-99.
3. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007;66:1316-21.
4. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991;49:163-75.
5. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004;43:1219-23.
6. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-43.
7. Roubenoff R, Heymsfield SB, Kehayias JJ, Cannon JG, Rosenberg IH. Standardization of nomenclature of body composition in weight loss. Am J Clin Nutr 1997;66:192-6.
8. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231-43.
9. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002;29:462-6.
10. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994;93:2379-86.
11. Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994;267:E331-6.
12. Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, et al. Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum 2002;46:2574-7.
13. Lemmey A, Maddison P, Breslin A, Cassar P, Hasso N, McCann R, et al. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J Rheumatol 2001;28:29-34.
14. Denko CW, Malemud CJ. The serum growth hormone to somatostatin ratio is skewed upward in rheumatoid arthritis patients. Front Biosci 2004;9:1660-4.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
18. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:S59-65.
19. Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;15:116-22.
20. Persson C, Sjoden PO, Glimelius B. The Swedish version of the patient-generated subjective global assessment of nutritional status: gastrointestinal vs urological cancers. Clin Nutr 1999;18:71-7.
21. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;11:8-13.
22. Abernathy RP, Black DR. Healthy body weights: an alternative perspective. Am J Clin Nutr 1996;63:448S-451S.
23. Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. Int J Obes Relat Metab Disord 2002;26:953-60.
24. Kyle UG, Piccoli A, Pichard C. Body composition measurements: interpretation finally made easy for clinical use. Curr Opin Clin Nutr Metab Care 2003;6:387-93.
25. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):S1-113.
26. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991;124:620-9.
27. Hilding A, Brismar K, Degerblad M, Thoren M, Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995;80:2646-52.
28. Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984;107:563-70.
29. Unden AL, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin Endocrinol (Oxf) 2005;63:94-102.
30. Lindgren BF, Odar-Cederlof I, Ericsson F, Brismar K. Decreased bioavailability of insulin-like growth factor-I: a cause of catabolism in hemodialysis patients? Growth Regul 1996;6:137-43.
31. Ponzer S, Tidermark J, Brismar K, Soderqvist A, Cederholm T. Nutritional status, insulin-like growth factor-1 and quality of life in elderly women with hip fractures. Clin Nutr 1999;18:241-6.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
33. Rajamand N, Ungerstedt U, Brismar K. Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus. Diabetes Obes Metab 2005;7:525-35.
34. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995;269:R1204-12.
35. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994;42:145-51.
36. Frystyk J, Hojlund K, Rasmussen KN, Jorgensen SP, Wildner-Christensen M, Orskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 2002;87:260-6.
37. Brismar K. The IGF and IGFBP system in insulin resistance and diabetes mellitus. In Houston MS, Holly JMP, Feldman EL, editors, Totowa, NJ: Humana Press, 2004.
38. Frost RA, Lang CH. Growth factors in critical illness: regulation and therapeutic aspects. Curr Opin Clin Nutr Metab Care 1998;1:195-204.
39. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998;18:277-82.
40. Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome - a study in borderline hypertension. Blood Press 1998;7:89-95.
41. Wolk K, Larsson SC, Vessby B, Wolk A, Brismar K. Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. J Clin Endocrinol Metab 2004;89:1879-84.
42. Morgan SL, Anderson AM, Hood SM, Matthews PA, Lee JY, Alarcon GS. Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis. Arthritis Care Res 1997;10:9-17.
43. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992;74:1355-60.
44. Pekonen F, Laatikainen T, Buyalos R, Rutanen EM. Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease. Fertil Steril 1989;51:972-5.
45. Paolisso G, Valentini G, Giugliano D, Marrazzo G, Tirri R, Gallo M, et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991;40:902-7.
46. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007;36:91-6.
47. Nygren J, Sammann M, Malm M, Efendic S, Hall K, Brismar K, et al. Distributed anabolic hormonal patterns in burned patients: the relation to glucagon. Clin Endocrinol (Oxf) 1995;43:491-500.
48. Mesotten D, Delhanty PJ, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 2002;87:5516-23.
49. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266-72.
50. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
51. Oster MH, Fielder PJ, Levin N, Cronin MJ. Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest 1995;95:2258-65.
52. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 1995;80:443-9.
53. Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev 2002;11:1441-8.
54. Persson M, Hytter-Landahl A, Brismar K, Cederholm T. Nutritional supplementation and dietary advice in geriatric patients at risk of malnutrition. Clin Nutr 2007;26:216-24.
55. Marcora SM, Lemmey AB, Maddison PJ. Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 2005;32:1031-9.
56. Rall LC, Meydani SN, Kehayias JJ, Dawson-Hughes B, Roubenoff R. The effect of progressive resistance training in rheumatoid arthritis. Increased strength without changes in energy balance or body composition. Arthritis Rheum 1996;39:415-26.
57. Marcora S, Lemmey A, Maddison P. Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr 2005;24:442-54.
58. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-72.
59. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007;46:1824-7.
60. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005;64:1137-40.
61. Karatay S, Yildirim K, Melikoglu MA, Akcay F, Senel K. Effects of dynamic exercise on circulating IGF-1 and IGFBP-3 levels in patients with rheumatoid arthritis or ankylosing spondylitis. Clin Rheumatol 2007;26:1635-9.
62. Phillips LS, Harp JB, Goldstein S, Klein J, Pao CI. Regulation and action of insulin-like growth factors at the cellular level. Proc Nutr Soc 1990;49:451-8.